IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Ranbaxy Buys 13 Drugs from BMS

7:04 AM MDT | August 6, 2007 | Chemical Week Editorial Staff

Ranbaxy Laboratories Inc. (RLI; Princeton, NJ), a wholly owned subsidiary of Ranbaxy Laboratories (Gurgaon, India), says it has acquired the U.S. rights to 13 dermatology products from Bristol-Myers Squibb (BMS). The U.S. dermatology market is valued at about $10 billion/year. The acquired brands have been in the market for more than a decade. They will be sold in the U.S. market under the RLI label. The deal “enables Ranbaxy to establish an immediate presence in the high-value segments of dermatitis, psoriasis, antifungals, and scabies, in addition to...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa